January 21, 2014 | Israeli company Pluristem Therapeutics, which develops placenta-based cell therapies, has announced tthe results from its Phase I/II clinical trial of PLacental eXpanded (PLX-PAD) cells in the treatment of muscle injury. The trial indicated PLX-PAD cells were safe and statistical significance was reached.
Related posts
Clean Energy Company That Mimics The Sun Raises $22M
February 02, 2023
Blood Test Offers Hope For Lung Cancer Patients
February 02, 2023
Israel Opens Its First Satellite Observatory
February 02, 2023
Cloud Data-Securing Startup Raises $30M
February 01, 2023
Facebook comments